{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:27:30Z","timestamp":1772771250483,"version":"3.50.1"},"reference-count":117,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.berh.2022.101811","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T07:49:11Z","timestamp":1671695351000},"page":"101811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Novel therapies in axial spondyloarthritis"],"prefix":"10.1016","volume":"36","author":[{"given":"Mohamad","family":"Bittar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Mease","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.berh.2022.101811_bib1","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s10067-005-0132-y","article-title":"Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis--a population-based survey","volume":"25","author":"Zochling","year":"2006","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2022.101811_bib2","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar3369","article-title":"Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study","volume":"13","author":"Arends","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.berh.2022.101811_bib3","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12325-012-0037-5","article-title":"Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings","volume":"29","author":"Bonafede","year":"2012","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.berh.2022.101811_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"Pt 8","key":"10.1016\/j.berh.2022.101811_bib5","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J Cell Sci"},{"issue":"4","key":"10.1016\/j.berh.2022.101811_bib6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/BOR.0000000000000399","article-title":"Janus kinase\/signal transducer and activator of transcription pathways in spondyloarthritis","volume":"29","author":"Raychaudhuri","year":"2017","journal-title":"Curr Opin Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2022.101811_bib7","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/annrheumdis-2016-210886","article-title":"Tracking JAKs in spondyloarthritis: rationale and expectations","volume":"76","author":"Miceli-Richard","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2022.101811_bib8","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/rheumatology\/keab740","article-title":"A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition","volume":"61","author":"McInnes","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.berh.2022.101811_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-34026-1","article-title":"Inhibiting ex-vivo Th17 responses in Ankylosing Spondylitis by targeting Janus kinases","volume":"8","author":"Hammitzsch","year":"2018","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.berh.2022.101811_bib10","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1172\/JCI126567","article-title":"TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis","volume":"130","author":"Gracey","year":"2020","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.berh.2022.101811_bib11","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.berh.2022.101811_bib12","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2022.101811_bib13","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/key104","article-title":"Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients","volume":"57","author":"Maksymowych","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.berh.2022.101811_bib14","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2022.101811_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002253","article-title":"Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial","volume":"8","author":"Navarro-Compan","year":"2022","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.berh.2022.101811_bib16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2022.101811_bib17","unstructured":"FDA. Fda requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions 2022 [Available from: https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death."},{"key":"10.1016\/j.berh.2022.101811_bib18","first-page":"641","article-title":"Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells","volume":"26","author":"Bing","year":"2020","journal-title":"Mol Vis"},{"key":"10.1016\/j.berh.2022.101811_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis","volume":"13","author":"Paley","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"6","key":"10.1016\/j.berh.2022.101811_bib21","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1053\/gast.1996.v110.pm8964393","article-title":"Long-term evolution of gut inflammation in patients with spondyloarthropathy","volume":"110","author":"De Vos","year":"1996","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.berh.2022.101811_bib22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202135","article-title":"Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model","volume":"72","author":"Van Praet","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"18","key":"10.1016\/j.berh.2022.101811_bib23","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.berh.2022.101811_bib24","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Panes","year":"2017","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.berh.2022.101811_bib25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","article-title":"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2022.101811_bib26","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.berh.2022.101811_bib27","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/acr.24025","article-title":"Update of the American College of rheumatology\/spondylitis association of America\/spondyloarthritis research and treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Care Res 2019"},{"key":"10.1016\/j.berh.2022.101811_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.berh.2022.101811_bib29","series-title":"Insa winzenborg , in-Ho song and ahmed othman exposure-response analyses for upadacitinib efficacy and safety in ankylosing spondylitis \u2013 analyses of the SELECT-AXIS I study","author":"Mohamed Ismail","year":"2019"},{"issue":"10214","key":"10.1016\/j.berh.2022.101811_bib30","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.berh.2022.101811_bib31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/art.41911","article-title":"Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and open-label extension","volume":"74","author":"Deodhar","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2022.101811_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002049","article-title":"Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials","volume":"8","author":"McInnes","year":"2022","journal-title":"RMD Open"},{"issue":"10349","key":"10.1016\/j.berh.2022.101811_bib33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.berh.2022.101811_bib34","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/ard-2022-222608","article-title":"Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial","volume":"81","author":"van der Heijde","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2022.101811_bib35","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with crohn's disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"10341","key":"10.1016\/j.berh.2022.101811_bib36","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.berh.2022.101811_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001838","article-title":"Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study","volume":"7","author":"McInnes","year":"2021","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.berh.2022.101811_bib38","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"10162","key":"10.1016\/j.berh.2022.101811_bib39","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.berh.2022.101811_bib40","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2022.101811_bib41","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/rheumatology\/keab543","article-title":"Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial)","volume":"61","author":"Maksymowych","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.berh.2022.101811_bib42","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/rheumatology\/keab758","article-title":"Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial","volume":"61","author":"Maksymowych","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2022.101811_bib43","unstructured":"Study to evaluate the efficacy and safety of filgotinib in participants with active ankylosing spondylitis who have an inadequate response to biologic disease-modifying antirheumatic drug therapy (SEALION1-IR) ClinicalTrials.gov [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04483687?term=SEALION1-IR&draw=2&rank=1."},{"issue":"7","key":"10.1016\/j.berh.2022.101811_bib44","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1007\/s12325-022-02168-4","article-title":"MANTA and MANTA-RAy: rationale and design of trials evaluating effects of filgotinib on semen parameters in patients with inflammatory diseases","volume":"39","author":"Hellstrom","year":"2022","journal-title":"Adv Ther"},{"issue":"8","key":"10.1016\/j.berh.2022.101811_bib45","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1007\/s10792-021-01851-9","article-title":"Protective effect of filgotinib in rat endotoxin-induced uveitis model","volume":"41","author":"Erdag","year":"2021","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.berh.2022.101811_bib46","unstructured":"Study to evaluate the efficacy and safety of filgotinib in adults with active noninfectious uveitis (HUMBOLDT) ClinicalTrials.gov [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03207815?term=HUMBOLDT&draw=2&rank=1."},{"issue":"10066","key":"10.1016\/j.berh.2022.101811_bib47","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"issue":"10292","key":"10.1016\/j.berh.2022.101811_bib48","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"issue":"10162","key":"10.1016\/j.berh.2022.101811_bib49","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101811_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.685280","article-title":"From science to success? Targeting tyrosine kinase 2 in spondyloarthritis and related chronic inflammatory diseases","volume":"12","author":"Hromadova","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.berh.2022.101811_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.591176","article-title":"Impact of Janus kinase inhibition on the treatment of axial spondyloarthropathies","volume":"11","author":"Hammitzsch","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2022.101811_bib52","series-title":"An oral Tyk2 inhibitor effectively suppresses the development of murine Th17 cells in vivo and prevents joint damage in experimental ankylosing spondylitis","author":"Eric Gracey","year":"2017"},{"key":"10.1016\/j.berh.2022.101811_bib53","series-title":"BMS-986165 is a highly potent and selective allosteric inhibitor of Tyk2, blocks IL-12, IL-23 and type I interferon signaling and provides for robust efficacy in preclinical models of systemic lupus erythematosus and inflammatory bowel disease","author":"Kathleen Gillooly","year":"2016"},{"issue":"14","key":"10.1016\/j.berh.2022.101811_bib54","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.berh.2022.101811_bib55","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"10.1016\/j.berh.2022.101811_bib56","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.berh.2022.101811_bib57","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, double-blind, placebo-controlled trial","volume":"140","author":"Forman","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.berh.2022.101811_bib58","series-title":"Efficacy and safety of brepocitinib (tyrosine kinase 2\/janus kinase 1 inhibitor) for the treatment of active psoriatic arthritis: results from a phase 2b randomized controlled trial","author":"Philip Mease","year":"2021"},{"key":"10.1016\/j.berh.2022.101811_bib59","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ajo.2021.01.007","article-title":"Identifying RNA biomarkers and molecular pathways involved in multiple subtypes of uveitis","volume":"226","author":"Rosenbaum","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.berh.2022.101811_bib60","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1084\/jem.20140280","article-title":"Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome","volume":"212","author":"Kreins","year":"2015","journal-title":"J Exp Med"},{"issue":"21","key":"10.1016\/j.berh.2022.101811_bib61","doi-asserted-by":"crossref","first-page":"10430","DOI":"10.1073\/pnas.1903561116","article-title":"Homozygosity for TYK2 P1104A underlies tuberculosis in about 1% of patients in a cohort of European ancestry","volume":"116","author":"Kerner","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.berh.2022.101811_bib62","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11926-022-01084-4","article-title":"Inhibiting IL-17a and IL-17F in rheumatic disease: therapeutics help to elucidate disease mechanisms","volume":"24","author":"Tam","year":"2022","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.berh.2022.101811_bib63","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"beta-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"19","key":"10.1016\/j.berh.2022.101811_bib64","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1093\/emboj\/20.19.5332","article-title":"IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding","volume":"20","author":"Hymowitz","year":"2001","journal-title":"EMBO J"},{"issue":"21","key":"10.1016\/j.berh.2022.101811_bib65","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.7150\/thno.29313","article-title":"Delivery of miR-146a to Ly6C(high) monocytes inhibits pathogenic bone erosion in inflammatory arthritis","volume":"8","author":"Ammari","year":"2018","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.berh.2022.101811_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001306","article-title":"Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells","volume":"6","author":"Shah","year":"2020","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.berh.2022.101811_bib67","first-page":"27","article-title":"Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults","volume":"38","author":"Erdes","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2022.101811_bib68","unstructured":"V. I. Mazurov Sfe, I. Z. Gaydukova, T. V. Dubinina, et al. Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5\/ASTERA [Available from: https:\/\/mrj.ima-press.net\/mrj\/article\/view\/1067?locale=en_US."},{"key":"10.1016\/j.berh.2022.101811_bib69","unstructured":"I. Gaydukova Vm, S. Erdes, T. Dubinina, et al.. OP0142 netakimab reduces ankylosing spondylitis activity in patients with or without sacroiliits on MRI: results of subanalysis of phase 3 ASTERA trial."},{"key":"10.1016\/j.berh.2022.101811_bib70","unstructured":"S. Erdes Vm, T. Dubinina, I. Gaydukova, et al.. POS0928 netakimab efficacy in anti-TNF-naive and anti-TNF-experienced patients with active Ankylosing spondylitis: results of subanalysis of phase 3 ASTERA trial."},{"issue":"5","key":"10.1016\/j.berh.2022.101811_bib71","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"79","author":"van der Heijde","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2022.101811_bib72","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/art.42282","article-title":"Safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 3-year results from a phase 2b randomized controlled trial and its open-label extension study","volume":"74","author":"Baraliakos","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2022.101811_bib73","series-title":"POS0939 bimekizumab in patients with active NON-radiographic axial spondyloarthritis: 24-WEEK efficacy & safety from be MOBILE 1, a phase 3, multicentre, randomised, placebo-controlled study","author":"Deodhar DvdH","year":"2022"},{"key":"10.1016\/j.berh.2022.101811_bib74","series-title":"OP0019 bimekizumab in patients with active ankylosing spondylitis: 24-WEEK efficacy & safety from be MOBILE 2, a phase 3, multicentre, randomised, placebo-controlled study EULAR","author":"Van der Heijde Xb","year":"2022"},{"issue":"10273","key":"10.1016\/j.berh.2022.101811_bib75","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.berh.2022.101811_bib76","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.berh.2022.101811_bib77","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.berh.2022.101811_bib78","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.berh.2022.101811_bib79","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study","volume":"76","author":"Sieper","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10163","key":"10.1016\/j.berh.2022.101811_bib80","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101811_bib81","unstructured":"F. Behrens Pct, D. Wetzel, N. C. Brun, et al. OP0258 izokibep (ABY-035) IN Patients with active psoriatic arthritis \u2013 16-WEEK results from a phase 2 study."},{"issue":"10284","key":"10.1016\/j.berh.2022.101811_bib84","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.berh.2022.101811_bib86","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1517\/14728222.12.8.921","article-title":"MK2: a novel molecular target for anti-inflammatory therapy","volume":"12","author":"Duraisamy","year":"2008","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"10.1016\/j.berh.2022.101811_bib87","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.pharep.2017.03.023","article-title":"Biological functions and role of mitogen-activated protein kinase activated protein kinase 2 (MK2) in inflammatory diseases","volume":"69","author":"Singh","year":"2017","journal-title":"Pharmacol Rep"},{"issue":"5","key":"10.1016\/j.berh.2022.101811_bib88","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/art.24485","article-title":"Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies","volume":"60","author":"Damjanov","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.berh.2022.101811_bib89","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2174\/1568026054985911","article-title":"Potential adverse effects associated with inhibition of p38alpha\/beta MAP kinases","volume":"5","author":"Dambach","year":"2005","journal-title":"Curr Top Med Chem"},{"issue":"3","key":"10.1016\/j.berh.2022.101811_bib90","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.4049\/jimmunol.177.3.1913","article-title":"MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis","volume":"177","author":"Hegen","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.berh.2022.101811_bib91","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.trsl.2022.06.005","article-title":"Discovery of CC-99677, a selective targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune disorders","volume":"249","author":"Malona","year":"2022","journal-title":"Transl Res"},{"key":"10.1016\/j.berh.2022.101811_bib92","series-title":"CC-99677, a novel, selective, oral MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production and ameliorates inflammation in the mannan-induced murine model of psoriasis and psoriatic arthritis","author":"Rajula Gaur","year":"2021"},{"key":"10.1016\/j.berh.2022.101811_bib93","series-title":"CC-99677: a novel, oral, selective MK2 inhibitor with sustainable multi-cytokine inhibition for the treatment of ankylosing spondylitis and other inflammatory diseases","author":"Kofi Mensah","year":"2021"},{"issue":"3","key":"10.1016\/j.berh.2022.101811_bib94","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/labinvest.2012.177","article-title":"Inhibition of p38\/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis","volume":"93","author":"Li","year":"2013","journal-title":"Lab Invest"},{"issue":"3","key":"10.1016\/j.berh.2022.101811_bib95","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.4049\/jimmunol.176.3.1431","article-title":"Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2","volume":"176","author":"Johansen","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.berh.2022.101811_bib96","first-page":"123","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the MK2 inhibitor ATI-450 in healthy subjects: a placebo-controlled, randomized phase 1 study","volume":"13","author":"Gordon","year":"2021","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.berh.2022.101811_bib97","first-page":"115","article-title":"The nature of allergy in tuberculosis at revealed by tissue culture studies","volume":"50","author":"Rich","year":"1932","journal-title":"Bull Johns Hopkins Hosp"},{"issue":"9","key":"10.1016\/j.berh.2022.101811_bib98","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/14728222.2019.1656718","article-title":"Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus","volume":"23","author":"Bilsborrow","year":"2019","journal-title":"Expert Opin Ther Targets"},{"issue":"11","key":"10.1016\/j.berh.2022.101811_bib99","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ni720","article-title":"Development of chronic colitis is dependent on the cytokine MIF","volume":"2","author":"de Jong","year":"2001","journal-title":"Nat Immunol"},{"issue":"9","key":"10.1016\/j.berh.2022.101811_bib100","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/art.40175","article-title":"Macrophage migration inhibitory factor induces inflammation and predicts spinal progression in ankylosing spondylitis","volume":"69","author":"Ranganathan","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2022.101811_bib101","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11926-022-01081-7","article-title":"Deep insight into the role of MIF in spondyloarthritis","volume":"24","author":"Wu","year":"2022","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"10.1016\/j.berh.2022.101811_bib102","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1136\/annrheumdis-2012-202177","article-title":"High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2022.101811_bib103","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.40777","article-title":"Sensitivity and specificity of autoantibodies against CD74 in nonradiographic axial spondyloarthritis","volume":"71","author":"Riechers","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"616","key":"10.1016\/j.berh.2022.101811_bib104","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg1210","article-title":"Macrophage migration inhibitory factor drives pathology in a mouse model of spondyloarthritis and is associated with human disease","volume":"13","author":"Nakamura","year":"2021","journal-title":"Sci Transl Med"},{"issue":"49","key":"10.1016\/j.berh.2022.101811_bib105","doi-asserted-by":"crossref","first-page":"E7917","DOI":"10.1073\/pnas.1612717113","article-title":"MIF allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritis","volume":"113","author":"Yoo","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.berh.2022.101811_bib106","first-page":"247","article-title":"Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis","volume":"40","author":"Kitaichi","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.berh.2022.101811_bib107","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/cei.12710","article-title":"Modulating of ocular inflammation with macrophage migration inhibitory factor is associated with notch signalling in experimental autoimmune uveitis","volume":"183","author":"Yang","year":"2016","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.berh.2022.101811_bib108","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13328","article-title":"17-a-estradiol late in life extends lifespan in aging UM-HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex","volume":"20","author":"Harrison","year":"2021","journal-title":"Aging Cell"},{"issue":"9","key":"10.1016\/j.berh.2022.101811_bib109","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1111\/bcp.14289","article-title":"Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours","volume":"86","author":"Mahalingam","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.berh.2022.101811_bib110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/ITT.S262566","article-title":"GM-CSF: A promising target in inflammation and autoimmunity","volume":"9","author":"Lee","year":"2020","journal-title":"ImmunoTargets Ther"},{"issue":"1","key":"10.1016\/j.berh.2022.101811_bib111","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190945","article-title":"GM-CSF in inflammation","volume":"217","author":"Hamilton","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.berh.2022.101811_bib112","series-title":"OP0107 serum granulocyte-monocyte colony stimulating factor (GM-CSF) IS increased in patients with active ankylosing spondylitis (as) and persists despite anti-TNF treatment","author":"Papagoras St","year":"2022"},{"issue":"1","key":"10.1016\/j.berh.2022.101811_bib113","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41467-019-13853-4","article-title":"GM-CSF drives dysregulated hematopoietic stem cell activity and pathogenic extramedullary myelopoiesis in experimental spondyloarthritis","volume":"11","author":"Regan-Komito","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.berh.2022.101811_bib114","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11926-021-00995-y","article-title":"Recent updates in the immunopathology of type 3 immunity-mediated enthesitis","volume":"23","author":"Nakamura","year":"2021","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"10.1016\/j.berh.2022.101811_bib117","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/bjd.17195","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody","volume":"180","author":"Papp","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.berh.2022.101811_bib118","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1080\/09273948.2019.1686156","article-title":"Preliminary report on interleukin-22, GM-CSF, and IL-17F in the pathogenesis of acute anterior uveitis","volume":"29","author":"Huang","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.berh.2022.101811_bib119","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.10066","article-title":"ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation","volume":"5","author":"Pearson","year":"2016","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.berh.2022.101811_bib120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-019-1879-x","volume":"21","author":"Taylor","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.berh.2022.101811_bib121","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/13543784.2019.1631795","article-title":"Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis","volume":"28","author":"Crotti","year":"2019","journal-title":"Expet Opin Invest Drugs"},{"issue":"1","key":"10.1016\/j.berh.2022.101811_bib122","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12967-019-1774-x","article-title":"Protein inhibitor of activated STAT3 reduces peripheral arthritis and gut inflammation and regulates the Th17\/Treg cell imbalance via STAT3 signaling in a mouse model of spondyloarthritis","volume":"17","author":"Min","year":"2019","journal-title":"J Transl Med"},{"issue":"10","key":"10.1016\/j.berh.2022.101811_bib123","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/blood-2008-06-162594","article-title":"PIAS3 negatively regulates RANKL-mediated osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblasts","volume":"113","author":"Hikata","year":"2009","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694222000705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694222000705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:22:29Z","timestamp":1761499349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694222000705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":117,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1521694222000705"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2022.101811","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapies in axial spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2022.101811","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101811"}}